Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 410 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sterile Water Clear all
Completed Not applicable Interventional Results available

Extension Study for 43USSA1705

NCT04225273
View directory record Official record
Conditions
Nasolabial Folds
Interventions
Sculptra Aesthetic, Lidocaine HCL
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Scottsdale, Arizona • Bradenton, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 20, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Neuro Biomarkers of Smoking Behavior

NCT03811951
View directory record Official record
Conditions
Smoking Cessation
Interventions
Novolin R
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 20, 2026, 8:55 PM EDT
Completed No phase listed Observational

Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

NCT03276481
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 20, 2026, 8:55 PM EDT
Terminated Phase 1 Interventional

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

NCT00238173
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 20, 2026, 8:55 PM EDT
Not yet recruiting Phase 2 Interventional

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

NCT04563026
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Perio. Maint. With Diode LBR

NCT05276817
View directory record Official record
Conditions
Chronic Periodontitis
Interventions
Epic Diode, HP, Sham
Device · Drug
Lead sponsor
Biolase Inc
Industry
Eligibility
30 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 20, 2026, 8:55 PM EDT
Active, not recruiting Phase 2 Interventional Results available

RANKL Inhibition and Mammographic Breast Density

NCT04067726
View directory record Official record
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 8:55 PM EDT
Terminated Not applicable Interventional

Microbial Growth in Operative Splash Basins During Total Joint Arthroplasty

NCT04274517
View directory record Official record
Conditions
Periprosthetic Joint Infection
Interventions
Sterile Water, 3.5% Betadine, 0.05% Chlorhexidine Gluconate
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Challenge Pool of Norwalk Virus Inoculum

NCT00138476
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Placebo, Norwalk Virus
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 20, 2026, 8:55 PM EDT
Recruiting Not applicable Interventional

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835
View directory record Official record
Conditions
Pediatric Intestinal Failure
Interventions
KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
Device
Lead sponsor
SterileCare Inc.
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 20, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

NCT03189433
View directory record Official record
Conditions
Drug Toxicity Psychotropic Agents Psychostimulants
Interventions
Ryanodex (dantrolene sodium) for injectable suspension
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

NCT00103740
View directory record Official record
Conditions
Paget's Disease of Bone
Interventions
zoledronic acid, placebo to zoledronic acid, Risedronate, Placebo to risedronate, Calcium and vitamin D supplements
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
10
States / cities
Tucson, Arizona • Colorado Springs, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 20, 2026, 8:55 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

NCT06852768
View directory record Official record
Conditions
oGHVD
Interventions
d-MAPPS, Placebo, PI and Patient Masked
Biological · Other
Lead sponsor
Regenerative Ocular Immunobiologics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Beverly Hills, California • Huntington Beach, California • Palm Harbor, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Results available

The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity

NCT01587950
View directory record Official record
Conditions
Dentinal Hypersensitivity, Dental Pain
Interventions
Potassium Nitrate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 20, 2026, 8:55 PM EDT
Not listed Phase 1 Interventional

Evaluation of Ascorbate-Meglumine Therapeutic for SRS

NCT06433791
View directory record Official record
Conditions
Safety
Interventions
Ascorbate-Meglumine
Drug
Lead sponsor
LadeRx LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury

NCT00973674
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Premarin IV, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Force of Stream to Retrograde Fill Voiding Trial After Vaginal Apex Suspension

NCT02753920
View directory record Official record
Conditions
Vaginal Apical Prolapse
Interventions
voiding trial, Foley catheter
Other · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Results available

Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03687372
View directory record Official record
Conditions
Common Wart
Interventions
A-101, vehicle
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 20, 2026, 8:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 20, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial of Two Techniques to Assess Postoperative Voiding Function

NCT02150083
View directory record Official record
Conditions
Urinary Retention
Interventions
OR retrograde fill
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 20, 2026, 8:55 PM EDT
Completed No phase listed Observational

Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?

NCT01123096
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Cough Stress Test, 24 Hour Pad Test
Procedure · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Oct 20, 2026, 8:55 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

NCT02576561
View directory record Official record
Conditions
Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions
Interventions
TVGV-1, GPI-0100, Placebo
Biological
Lead sponsor
THEVAX Genetics Vaccine
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Lakewood, Colorado • Port Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 20, 2026, 8:55 PM EDT